---
document_datetime: 2025-08-13 16:04:59
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/breyanzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: breyanzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4393505
conversion_datetime: 2025-12-19 06:02:41.242524
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Breyanzi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 12/08/2025                          | N/A                                         |                                  | To update the RMP to add follicular lymphoma |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000288030                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP to add follicular lymphoma patients infused with liso-cel in the post marketing setting in the study population of study JCAR017 BCM- 005, based on the updated post- authorization safety study (PASS) protocol that was endorsed by PRAC. In addition, the MAH took the opportunity to implement an editorial change to correct the milestone dates for the Transgene assay service listed in Table 3.3-1, aligning them with the   |            |     | patients infused with liso-cel in the post marketing setting in the study population of study JCAR017 BCM-005, based on the updated post-authorization safety study (PASS) protocol that was endorsed by PRAC.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000273146 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted                                                                                                                                          | 04/08/2025 | N/A |                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000269488    | This was an application for a group of variations. B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted   | 25/07/2025   | N/A   |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type II / EMA/VR/0000249056    | B.I.e) Design Space and post-approval change management protocols - B.I.e.2 Introduction of a post approval change management protocol related to the active substance - Accepted                                                                                                                                                                                                                                                                                                         | 24/07/2025   | N/A   |
| PASS / EMA/PASS/0000269320               | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/07/2025   | N/A   |
| Variation type IA_IN / EMA/VR/0000272241 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended                                                                                                                                                                                                                                                                                     | 20/05/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

|                                          | Plasma Master File when changes do not affect the properties of the finished product - Accepted                                                                                                                                                                                                                                                                                                  |            |     |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000257499    | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to provide a consolidated Risk Management Plan (RMP) following a positive CHMP opinion for procedures EMEA/H/C/004731/II/0043/G and EMEA/H/C/004731/IB/0051. | 10/04/2025 | N/A |
| Variation type IA_IN / EMA/VR/0000246077 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted                                                                                            | 06/02/2025 | N/A |